All In Biotech

Drug Trial Radar · NCT00198991

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)

Last checked: Nov 19, 2026Latest source record: Aug 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,883

Actual

Start

Apr 2003

Primary completion

Jun 30, 2011

Study completion Jun 30, 2013

Sponsor

Lead sponsor
Goethe UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany); German Federal Ministry of Education and Research
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on the results of MRD evaluation.

Conditions

  • Adult Acute Lymphocytic Leukemia

Interventions

  • CyclophosphamideDrug

    Cytostatic drug

  • DexamethasoneDrug

    Antileukemic drug

  • VincristineDrug

    Cytostatic drug

  • DaunorubicinDrug

    Cytostatic drug

  • AsparaginaseDrug

    Cytostatic drug

  • MethotrexateDrug

    Cytostatic drug

  • CytarabineDrug

    Cytostatic drug

  • MercaptopurineDrug

    Cytostatic drug

  • G-CSFDrug

    Growth factor

  • VindesineDrug

    Cytostatic drug

  • EtoposideDrug

    Cytostatic drug

  • PrednisoloneDrug

    Antileukemic drug

  • AdriamycinDrug

    Cytostatic drug

  • ThioguanineDrug

    Cytostatic drug

  • TeniposideDrug

    Cytostatic drug

  • CNS irradiationProcedure

    Cytostatic drug

  • Mediastinal IrradiationProcedure

    Irradiation

  • Stem cell transplantation (SCT)Procedure

    Stem cell transplantation

  • IdarubicinDrug

    Cytostatic drug

  • FludarabineDrug

    Cytostatic drug

  • CladribineDrug

    Cytostatic drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission rateTime frame: day 46
  2. Remission durationTime frame: up to 10 years
  3. Disease free survivalTime frame: up to 10 years
  4. Overall survivalTime frame: up to 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Frankfurt, Medical Dept. II

    Frankfurt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.